HKPD earnings date and last-quarter result: P/E -5.17. Updated 2026-07-23.
Cellyan Biotechnology (HKPD) Research Hub
Cellyan Biotechnology (HKPD) trades on NASDAQ, HK in the Healthcare (Medical - Pharmaceuticals) sector. As of 2026-10-26, shares last closed at 2.19 USD (+2090.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.17, market cap 0.00B. This hub links to the full technical, earnings and options research available for HKPD.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Pharmaceuticals) |
|---|---|
| Exchange | NASDAQ, HK |
| Last close | 2.19 USD (+2090.00%) |
| 52-week range | 0.085 USD – 2.24 USD |
| Trend regime | Range |
| 14-day RSI | 98.6 (Overbought) |
| Trailing P/E | -5.17 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
Available research for HKPD
Covered Call on HKPD: how it works, illustrative setup around the real 2.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on HKPD: how it works, illustrative setup around the real 2.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on HKPD: how it works, illustrative setup around the real 2.19 USD price, max profit/loss, breakeven and when to use it. Educational.
HKPD technical analysis: range, last 2.19 USD, RSI 98.6, 52w range 0.085 USD–2.24 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is HKPD in?
Cellyan Biotechnology (HKPD) is classified under Healthcare (Medical - Pharmaceuticals), listed on NASDAQ, HK.
Is HKPD in an uptrend or downtrend?
As of 2026-10-26, HKPD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is HKPD's trailing P/E ratio?
HKPD's trailing P/E is -5.17, with a market cap of 0.00B. See the earnings research page for full valuation detail.